Mizuho Securities Reiterates Buy on Jazz Pharmaceuticals (JAZZ) Following Dinner Takeaway

September 15, 2016 7:35 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $102.32 +0.55%

Rating Summary:
    27 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade JAZZ Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Mizuho Securities reiterated a Buy rating and $185.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after hosting a dinner with the company.

Analyst Irina Koffler commented, "We hosted a dinner for Jazz on Sept 13. We believe that the company is working to strengthen its defenses in the Xyrem generic litigation via its 2033 Valproate patents while simultaneously advancing an intriguing life cycle extension, diversifying revenues via M&A, and aggressively repurchasing stock. Shares may remain range-bound ahead of meaningful developments in the Xyrem litigation, but we note that settlement can occur at any time."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $122.54 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Irina Koffler

Add Your Comment